Results 71 to 80 of about 63,359 (335)

In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2

Leukemia, 2022
Treatment options for patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are scarce. Recurring mutations, such as mutations in isocitrate dehydrogenase-1 and -2 (IDH1/2) are found in subsets of AML and MDS,
R. Gbyli, Yuanbin Song, W. Liu, Yimeng Gao, Giulia Biancon, Namrata S. Chandhok, Xiaman Wang, Xiaoying Fu, Amisha Patel, R. Sundaram, T. Tebaldi, Padmavathi Mamillapalli, A. Zeidan, R. Flavell, T. Prebet, R. Bindra, Stephanie Halene   +16 more
semanticscholar   +1 more source

Significance and Impact of Changing WHO Classification Systems on Glial Tumors with Special Reference to IDH1 Mutation in Resource-Limited Setups

Asian Pacific Journal of Cancer Biology, 2023
Objectives: To reclassify glial neoplasms according to the 2021 WHO CNS tumor classification and to study the expression pattern of Isocitrate dehydrogenase 1 (IDH1) mutation by immunohistochemistry(IHC) and to categorize these tumors on the basis of ...
Divya Singh, Vatsala Misra, Kachnar Varma   +2 more
doaj   +1 more source

In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma. [PDF]

, 2019
Dysregulation in NAD+/NADH levels is associated with increased cell division and elevated levels of reactive oxygen species in rapidly proliferating cancer cells.
Batsios, Georgios, Gillespie, Anne Marie, Le Page, Lydia M, Najac, Chloé, Radoul, Marina, Ronen, Sabrina M, Subramani, Elavarasan, Viswanath, Pavithra   +7 more
core   +3 more sources

Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia

Nature Communications, 2022
The interaction of germline variation and somatic cancer driver mutations is under-investigated. Here we describe the genomic mitochondrial landscape in adult acute myeloid leukaemia (AML) and show that rare variants affecting the nuclear- and ...
M. Bassal, S. Samaraweera, Kelly Lim, Brooks A. Benard, Sheree Bailey, Satinder Kaur, P. Leo, J. Toubia, Chloe A L Thompson-Peach, Tran Nguyen, K. Z. Y. Maung, D. A. Casolari, D. Iarossi, I. S. Pagani, J. Powell, S. Pitson, S. Natera, U. Roessner, I. Lewis, Anna L. Brown, D. Tenen, N. Robinson, D. Ross, R. Majeti, T. Gonda, Daniel Thomas, R. D’Andrea   +26 more
semanticscholar   +1 more source

IDH1(R132H) Immunoexpression in Glioma

Advanced Medical Journal, 2018
Background and objectives: Gliomas are the most common type of primary brain tumors. They result from accumu-- lation of multiple genetic alterations. Isocitrate dehydrogenase 1 mutations are detected in gliomas. This study aimed to assess IDH1 immunoexpression in different types of gliomas and to correlate the results with patient’s age, gender, tumor
Nyan Saeed Omer, Jalal Ali Jalal, Ava Tahir Ismael   +2 more
openaire   +2 more sources

The ketogenic diet is not effective in preclinical models of IDH1 wild-type and IDH1 mutant glioma [PDF]

, 2020
ABSTRACTInfiltrative gliomas are the most common neoplasms arising in the brain, and remain largely incurable despite decades of research. A subset of these gliomas contains mutations inisocitrate dehydrogenase 1(IDH1mut). This mutation disrupts cellular biochemistry, and IDH1mutgliomas are generally less aggressive than IDH1 wild-type (IDH1wt) gliomas.
Rodrigo Javier, Craig Horbinski
openaire   +2 more sources

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date

Cancer Management and Research, 2023
Pedro Luiz Serrano Uson Junior,1– 3 Mitesh J Borad1 1Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA; 2HCOR, Hospital do Coração, Sao Paulo, Brazil; 3Center for Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo ...
Uson Junior PLS, Borad MJ
doaj  

Expression of LOC285758, a potential long non-coding biomarker, is methylation-dependent and correlates with glioma malignancy grade

Radiology and Oncology, 2017
Identifying the early genetic drivers can help diagnose glioma tumours in their early stages, before becoming malignant. However, there is emerging evidence that disturbance of epigenetic mechanisms also contributes to cell’s malignant transformation and
Matjasic Alenka, Popovic Mara, Matos Bostjan, Glavac Damjan   +3 more
doaj   +1 more source

Impact of IDH1 Mutation on Long-Term Survival in Patients with Diffuse Glioma

Central Asian Journal of Medical Sciences, 2019
Objectives: Diffuse brain gliomas are common primary brain tumor associated with a poor prognosis. In this study, we aimed to determine the impact of IDH1 mutation status on long term survival.
Enkhee Ochirjav, Tuul Baldandorj, Gheeyoung Choe, Bayarmaa Enkhbat   +3 more
doaj   +1 more source

Novel therapeutic venues for glioblastoma: novel rising preclinical treatment opportunities [PDF]

, 2011
High grade gliomas, including anaplastic glioma WHO grade III and glioblastoma WHO IV (GBM), carry a dismal prognosis. Taking all nowadays-available therapeutics options, including radiation, chemotherapy and surgery, for GBM into consideration the ...
Siegelin, Markus David, Siegelin, Yasemin   +1 more
core   +1 more source